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Background: Cryptococcal meningoencephalitis is an opportunistic infection that predominantly affects
immunocompromised patients. Hyper immunoglobulin M syndrome is a primary immunodeficiency syndrome that
increases susceptibility to several opportunistic infections. Here, we report a case of cryptococcal meningoencephalitis
in the context of hyper immunoglobulin M syndrome, a situation that has been reported very few times and whose
management is not clearly defined. We describe our management of this case and the outcome of the patient to help
in future similar situations.
Case presentation: The patient is a 19-year-old Caucasian male student diagnosed with X-linked hyper immunoglobulin
M syndrome and treated chronically with weekly intravenous immunoglobulin and daily sulfamethoxazole-trimethoprim.
He was admitted to the infectious diseases ward because of headache, diplopia and a cerebral-spinal fluid analysis
revealing cryptococcal meningoencephalitis. The patient was treated with liposomal amphotericin and flucytosine
with a favorable outcome. Maintenance therapy with fluconazole has continued and will be sustained for 6 months
following his upcoming bone marrow transplantation.
Conclusion: Monitoring for cryptococcal meningoencephalitis should be considered in patients with primary
immunodeficiencies, as clinical manifestations may go unnoticed. In these patients, it is expected that chronic
treatment with fluconazole will be the only treatment that will prevent reinfection or reactivation, and therefore
should be kept at least until bone marrow transplant, the only curative treatment, is performed. It may, however,
lead to intolerable side effects and hepatic toxicity.
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Hyper immunoglobulin M (HIGM) syndrome is a primary
immunodeficiency (PID) that was described for the first
time in 1961 [1]. It is a well-known PID, classified as a
B-cell immunodeficiency and characterized by normal
to high immunoglobulin (Ig) M levels and absent IgG,
IgA and IgE due to an impairment of class switching
recombination [2]. It results from a mutation of the
CD154 gene that encodes for a T-cell membrane protein
(CD40 ligand), which is normally able to activate CD40 in
B-cells and antigen-presenting cells (APC). Impairment of* Correspondence: lmalha@gmail.com
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switching in B-cells, and a reduced ability of monocytes to
induce allogeneic T-cell proliferation (Figure 1). The net
result is an increased susceptibility to opportunistic infec-
tions by Pneumocystis jirovecii, Cryptosporidium spp., and
other intracellular organisms, and a higher rate of bacterial
and viral disseminated infections. In the majority of cases,
the condition has an X-linked inheritance, as is the case
with this report of a young adult male with Cryptococcus
neoformans meningoencephalitis.
Case presentation
On April 29th 2013, a 19-year-old Caucasian male student
was observed in the emergency department of our hos-
pital complaining of diplopia, which started 2 weeks prior,
and a mild frontal, bilateral, dull headache, persisting overal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Diagram of the immunologic effects of hyper IgM syndrome. A) In a healthy individual, the CD154 (CD40L)-CD40 interaction is
essential for antigen-presenting cell (APC) maturation and B-cell antigenic shift towards the production of IgG, IgA and IgE. APC maturation leads
to increased antigen-presenting capacity and phagocytic activity, as well as interleukin (IL) production that further stimulates T helper-1 (Th1) cell
differentiation. B) In X-linked hyper IgM syndrome, CD40L mutations decrease the capacity of T-cells to differentiate and interact with other
immune system cells, increasing susceptibility to opportunistic infections.
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fever, vomiting, nausea or any focal neurological signs. On
physical examination, only a bilateral mild papillary border
elevation was perceived by fundoscopy. Blood tests revealed
the following measurements: hemoglobin, 14.8 g/dL;
leucocytes, 9.02 × 109/L (neutrophils, 60%; lymphocytes,
21%); and platelets, 129 × 109/L. Blood chemistry showed
normal renal and hepatic function, but with a C-reactive
protein level of 17.3 mg/L (normal: <10 mg/L). The com-
puted tomography (CT) scan of the patient’s brain was
normal. A lumbar puncture (LP) was performed, which
resulted in the release of clear cerebral-spinal fluid (CSF)
and had an opening pressure of 33 cm H2O (normal:
7–14 cm H2O). Analysis of the CSF showed 120 leuco-
cytes per cubic millimeter with 94.2% mononuclear
cells, glucose levels <50% (43 mg/dL) of seric value
(normal: >50% of seric value), and 0.87 mg/mL of pro-
teins (normal: <0.5 mg/mL). The CSF cryptococcal
antigen test was negative. The patient was treated em-
pirically with ampicillin and ceftriaxone.
The patient’s medical history indicated that he had been
diagnosed with X-linked HIGM syndrome at the age of6 months in the setting of a severe Pneumocystis jirovecii
pneumonia with secondary bronchopulmonary dysplasia.
He has been treated chronically with weekly intravenous
immunoglobulin (IVIg) and daily sulfamethoxazole-
trimethoprim since 6 months of age. In spite of these
treatments, he had several lower respiratory tract infec-
tions during childhood. His parents are asymptomatic, but
his mother is a CD154 mutation carrier.
The CSF sample obtained on admission was sent to
the microbiology laboratory, where a Gram-stained smear,
a direct India ink exam, and blood and chocolate agar cul-
tures at 37°C and 5% CO2 were performed. While the re-
sults from the Gram stain and direct exam were negative,
after 24 hours of incubation, gray, mucoid colonies, highly
suspicious of Cryptococcus spp., were growing (Figure 2A).
A direct examination of the colonies suspended in dis-
tilled water revealed round cells in a range of sizes, sug-
gestive of yeast (Figure 2B). The identification of
Cryptococcus neoformans was provided by a Vitek2
System™ (bioMerieux™) and confirmed by matrix-assisted
laser desorption-ionization time-of-flight (Maldi-Tof™)
mass spectrometry with Vitek MS™ (bioMerieux™). The
Figure 2 Microscopic photographs of Cryptococcus neoformans. A) Gray, mucoid colonies, highly suspicious of Cryptococcus spp., growing in
solid media. B) Direct examination of colonies in suspension.
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chain reaction (PCR) assays testing for Mycobacterium tu-
berculosis and Listeria monocytogenes were negative.
Following these findings, the empirical treatment with
ampicillin and ceftriaxone was suspended and treatment
with liposomal amphotericin and flucytosine was begun.
Two days later, a second CSF sample, with 104 leuco-
cytes per cubic millimeter (57% lymphocytes and 7%
neutrophils) and an opening pressure of 22 cm H2O was
processed as described above. In this sample, the result
from the India ink exam was positive and the yeast
grown on the agar media were identified as Cryptococcus
neoformans by Vitek MS™. The CSF cryptococcal antigen
test was not repeated. The blood that had been collected
upon admission was microbiologically negative.
The patient’s symptoms cleared after 7 days of treat-
ment. Because of symptomatic improvement and the ab-
sence of increased intracranial pressure, regular evacuative
LPs were not performed. After 2 weeks of treatment, a LP
was repeated, yielding negative results from an India ink
stain, Gram stain and culture. The cryptococcal serum
antigen titer was 1:32. Treatment was changed to flu-
conazole (400 mg/day). During the length of his 18-day
admittance, the patient maintained his usual prophy-
lactic sulfamethoxazole-trimethoprim treatment and at
discharge he was asymptomatic, with a normal physical
exam. The patient remained on maintenance treatment
for C. neoformans.Discussion
Cryptococcus neoformans is an encapsulated yeast found
worldwide that is isolated predominantly from pigeon
droppings and soil contaminated with avian excreta [3].
It is not unusual for humans to come into contact with
it early in life, and a majority of children are likely to
have been exposed by the age of 5. This situation prob-
ably applies to our patient, as he was raised in a rural
area.
Inhalation of the yeast is the most frequent way of ac-
quiring this infection. From the lungs the fungal cells
may spread hematogenously to the brain, causing life-
threatening meningitis or meningoencephalitis, or even
to other organs. The disease can vary from localized to
disseminated and from acute to chronic depending on
the state of the patient’s immune system, which may be
impaired by malignancy, immunosuppressive therapies,
or acquired/primary immunosuppression syndromes, as
is the case for the patient described in this report.
There have been several attempts to gather information
about X-linked HIGM syndrome, though its rarity makes
the development of a comprehensive clinical picture of
this disease hard to achieve.
X-linked HIGM syndrome is expected to increase sus-
ceptibility to C. neoformans, as it has been shown to do
in vitro [4], although the in vivo incidence is not as great
as expected, evidenced by the fact that only a few cases
have been reported [5-8]. IVIg therapy, used widely in
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the frequency of lower respiratory tract infections and
severe infections; however, it does not change the frequency
of non-respiratory or upper respiratory infections [9].
In this patient the symptoms were less intense than
expected. Clinically, there were no major central ner-
vous system symptoms, apart from diplopia for far-
sighted focus, which lasted for 2 weeks, and headache
for the 2 days before admittance. There were no find-
ings in his blood that suggested an infection, and if it
were not for his medical history and high clinical suspi-
cion, a LP would not have been performed. Nonetheless,
a cerebral CT scan should always be done in a young pa-
tient presenting with headache and neurologic focal
signs for a long period. This lack of symptoms may re-
veal a decreased immune response to Cryptococcus spp.,
as it was shown that in vitro the CD154-CD40 inter-
action is essential for the secretion of IL-12 and IFNγ in
response to this organism [10]. If these cytokines are
not produced, the macrophages cannot activate T-cells
through antigen-presenting dendritic cells, decreasing
the rates of Th1 generation normally responsible for
stimulating phagocytic activity towards fungal infections
(Figure 1). As a consequence, the immune reaction will
be less severe, with reduced immune activation and mi-
gration and fewer symptoms typically due to meningeal
inflammation.
Amphotericin B and Flucytosine, suggested by current
practice guidelines, were effective therapies against Cryp-
tococcus neoformans as shown by the clinical improve-
ment and the negative lumbar puncture after 2 weeks of
combined treatment [11]. Although this treatment was
effective, there is no consensus on the appropriate dur-
ation for maintenance therapy. In the HIV setting, there
is evidence that maintenance therapy should be kept
until an immunologic improvement, characterized by
CD4+ T-cells > 100/μL for more than 3 months, is achieved
[12]. However, in the X-linked HIGM setting, there is no
evidence indicating whether to continue lifelong mainten-
ance therapy or to stop after a short treatment. Patients
with this disease are young, and lifelong therapy with flu-
conazole may lead to several side effects that can become
intolerable and lead to hepatic toxicity. There are no
methods, apart from bone marrow transplant (BMT), that
can provide immune recovery for these patients; therefore,
if they develop cryptococcal meningoencephalitis under
treatment with IVIg, we expect that fluconazole will be
the only treatment that will prevent reinfection or
reactivation.
Recently, evidence that allogeneic BMT may lead to cor-
rection of the immunodeficiency, with varying degrees of
success, has given new perspectives on this condition [13].
Our patient has been recommended to undergo BMT and
continue maintenance therapy with fluconazole until he ishealthy enough to undergo the procedure. However, after
the procedure he will be exposed to a new serious immu-
nodepression because of the necessary post-transplant
treatment with immunosuppressors, and a relapse of the
disease is possible. There are recommendations for pa-
tients that develop cryptococcal meningoencephalitis dur-
ing BMT, but none for patients with a previous history of
the disease, so the choice to keep maintenance therapy for
6–12 months after the procedure is debatable.
Conclusion
X-linked HIGM syndrome is characterized by a high
incidence of opportunistic infections with an unfavor-
able outcome, despite regular substitution therapy with
IVIg. However, outcomes will likely be improved with
additional therapies, like trimethoprim/sulfamethoxa-
zole prophylaxis, and close follow-up. If these methods
are successful, an older population of X-linked HIGM
patients will develop in time, and new opportunistic
infections that we are unaware of could also appear. In-
fections with Cryptococcus spp. may be more frequent
than described and deserve further studies to determine
treatment outcomes and duration.
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